A PHASE II TRIAL OF TUMOR TREATING FIELDS (TTFIELDS) CONCOMITANT WITH RADIOSURGERY FOR THE TREATMENT OF RECURRENT, BEVACIZUMAB-NAIVE GLIOBLASTOMA

被引：0
|
作者：
Harat, Maciej [1 ]
Blok, Maciej [2 ]
Adamczak-Sobczak, Magda [2 ]
Szymanski, Pawel [2 ]
Miechowicz, Iza [3 ]
Malkowski, Bogdan [1 ]
机构：
[1] Nicolaus Copernicus Univ, Coll Med, Bydgoszcz, Poland
[2] Prof Franciszek Lukaszczyk Oncol Ctr, Bydgoszcz, Poland
[3] Poznan Univ Med Sci, Poznan, Poland
来源：
NEURO-ONCOLOGY | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CTNI-46
引用
收藏
页码：52 / 53
页数：3
相关论文
共 50 条
  • [1] TRIAL IN PROGRESS: CA209-9Y8 PHASE 2 TRIAL OF TUMOR TREATING FIELDS (TTFS), NIVOLUMAB PLUS/MINUS IPILIMUMAB FOR BEVACIZUMAB-NAIVE, RECURRENT GLIOBLASTOMA
    Odia, Yazmin
    Iwamoto, Fabio
    NEURO-ONCOLOGY, 2019, 21 : 3 - 3
  • [2] Phase II study of dianhydrogalactitol in patients with MGMT-unmethylated bevacizumab-naive recurrent glioblastoma
    O'Brien, Barbara J.
    Bacha, Jeffrey A.
    Brown, Dennis M.
    Steino, Anne
    Schwartz, Richard
    Kanekal, Sarath
    Lopez, Lorena
    Penas-Prado, Marta
    CANCER RESEARCH, 2017, 77
  • [3] Phase II study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naive recurrent glioblastoma
    O'Brien, Barbara
    De Groot, John
    Kamiya-Matsuoka, Carlos
    Weathers, Shiao-Pei
    Bacha, Jeffrey
    Brown, Dennis
    Steino, Anne
    Langlands, John
    Schwartz, Richard
    Kanekal, Sarath
    Lopez, Lorena
    Penas-Prado, Marta
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Phase II study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naive recurrent glioblastoma, MGMT-unmethylated
    O'Brien, Barbara J.
    De Groot, John
    Kamiya-Matsuoka, Carlos
    Weathers, Shiao-Pei
    Bacha, Jeffrey A.
    Brown, Dennis M.
    Steino, Anne
    Langlands, John
    Schwartz, Richard
    Kanekal, Sarath
    Lopez, Lorena
    Penas-Prado, Marta
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment
    Vergote, Ignace
    Macarulla, Teresa
    Hirsch, Fred R.
    Hagemann, Carsten
    Miller, David Scott
    CANCERS, 2023, 15 (03)
  • [6] PHASE 3 TRIDENT TRIAL: CONCOMITANT RADIATION THERAPY (RT) AND TEMOZOLOMIDE plus /- TUMOR TREATING FIELDS (TTFIELDS) IN NEWLY DIAGNOSED GLIOBLASTOMA
    Shi, Wenyin
    Kleinberg, Lawrence
    Jeyapalan, Suriya A.
    Goldlust, Samuel
    Nagpal, Seema
    Combs, Stephanie E.
    Roberge, David
    Nishigawa, Ryo
    Grossman, Rachel
    Glas, Martin
    NEURO-ONCOLOGY, 2020, 22 : 59 - 60
  • [7] THE EFFICACY OF TEMOZOLOMIDE AND LOMUSTINE IN GLIOBLASTOMA CELL LINES MAY BE ENHANCED BY CONCOMITANT TREATMENT WITH TUMOR TREATING FIELDS (TTFIELDS)
    Fishman, Hila
    Monin, Roni
    Dor-On, Eyal
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    NEURO-ONCOLOGY, 2022, 24 : 92 - 92
  • [8] PRICOTTF: A PHASE I/II TRIAL OF TUMOR TREATING FIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
    Glas, M.
    Scheffler, B.
    Lazaridis, L.
    Herrlinger, U.
    Pierscianek, D.
    Sure, U.
    Proescholdt, M.
    Hau, P.
    Hense, J.
    Kleinschnitz, C.
    Grosu, A.
    Stuschke, M.
    Kebir, S.
    NEURO-ONCOLOGY, 2018, 20 : 243 - 243
  • [9] PriCoTTF: A PHASE I/II TRIAL OF TUMOR TREATING FIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
    Glas, Martin
    Scheffler, Bjoern
    Lazaridis, Lazaros
    Herrlinger, Ulrich
    Pierscianek, Daniela
    Sure, Ulrich
    Proescholdt, Martin
    Hau, Peter
    Hense, Joerg
    Kleinschnitz, Christoph
    Grosu, Anca-Ligia
    Stuschke, Martin
    Kebir, Sied
    NEURO-ONCOLOGY, 2018, 20 : 22 - 22
  • [10] REPORT ON THE COMBINATION OF AXITINIB AND TUMOR TREATING FIELDS (TTFIELDS) IN THREE PATIENTS WITH RECURRENT GLIOBLASTOMA
    Schulz, Ellina
    Kessler, Almuth F.
    Weiland, Judith
    Linsenmann, Thomas
    Ernestus, Ralf-Ingo
    Hagemann, Carsten
    Loehr, Mario
    NEURO-ONCOLOGY, 2019, 21 : 16 - 16
12345